Association between anti-Porphyromonas gingivalis or anti-α-enolase antibody and severity of periodontitis or rheumatoid arthritis (RA) disease activity in RA.
Association between anti-Porphyromonas gingivalis or anti-α-enolase antibody and severity of periodontitis or rheumatoid arthritis (RA) disease activity in RA.
复制标题
DOI：
10.1186/s12891-015-0647-6
复制
发表时间：
2015-08-12
影响因子：
2.3
通讯作者：
Song YW
中科院分区：
文献类型：
--
作者：
Lee JY;Choi IA;Kim JH;Kim KH;Lee EY;Lee EB;Lee YM;Song YW
牙周炎(PD)被认为与类风湿性关节炎(RA)有关。牙龈卟啉单胞菌(P.gigivalis)是一种革兰氏阴性厌氧菌，被认为是PD的主要病原菌之一，也是目前已知的唯一表达肽基精氨酸脱亚氨酶(PAD)的细菌。抗人α-enolase抗体是类风湿关节炎的自身抗体之一。ENO1是一种高度保守的蛋白质，可能成为细菌和人类蛋白质分子模拟的候选分子。在本研究中，我们检测了RA患者血清中抗牙龈假单胞菌抗体和人类ENO1抗体，并探讨了它们与PD严重程度或RA疾病活动性的关系。对248例类风湿关节炎患者和85例年龄、性别相匹配的健康对照进行了风湿学和牙周检查。血清抗P。采用酶联免疫吸附试验(ELISA)检测牙周炎和抗ENO1抗体。类风湿关节炎患者血清抗P-P水平显著升高。牙周炎和抗eNO1抗体滴度均高于对照组(p = 分别为0.002和0.0001)。抗P。RA患者牙龈抗体滴度与抗eNO1抗体滴度显著相关(r = 0.30，p <； 0.0001)。抗-P之间存在显著的相关性。RA患者的牙龈抗体滴度与牙龈指数、探诊袋深、探诊时出血和临床附着水平(p = 分别为0.038、0.004、0.004和0.002)有关。抗P。牙龈抗体滴度与疾病活动性评分28(DAS28)或抗CCP滴度无关。然而，抗eNO1抗体滴度不仅与牙周指数相关(p = 分别为0.013、0.023和0.017)，还与类风湿关节炎的临床特征如DAS28、抗CCP滴度和血沉相关(p = 分别为0.009、0.015和0.001)。抗P。牙周炎和抗ENO1抗体滴度与RA帕金森病的严重程度相关。抗ENO1抗体效价较高，但抗P。牙周炎抗体滴度与RA疾病活动性进一步相关。本文的在线版本(doi：10.1186/s12891-0150647-6)包含补充材料，授权用户可以使用。
Periodontitis (PD) has been reported to be associated with rheumatoid arthritis (RA). Porphyromonas gingivalis (P. gingivalis) is a gram-negative anaerobic bacterium that is recognized as one of the major pathogenic organisms in PD and is the only bacterium known to express peptidylarginine deiminase (PAD). Antibody against human α-enolase (ENO1) is one of the autoantibodies in RA. ENO1 is a highly conserved protein, and could be a candidate molecule for molecular mimicry between bacterial and human proteins. In the present study, we measured serum antibody against P. gingivalis and human ENO1 in patients with RA and investigated their association with the severity of PD or disease activity of RA. Two hundred, forty-eight patients with RA and 85 age- and sex-matched healthy controls were evaluated by rheumatologic and periodontal examinations. The serum levels of anti-P. gingivalis and anti-ENO1 antibodies were measured by an enzyme-linked immunosorbent assay (ELISA). Patients with RA had significantly higher levels of anti-P. gingivalis and anti-ENO1 antibody titers than the controls (p = 0.002 and 0.0001, respectively). Anti-P. gingivalis antibody titers significantly correlated with anti-ENO1 antibody titers in RA patients (r = 0.30, p < 0.0001). There were significant correlations between anti-P. gingivalis antibody titers and the gingival index (GI), probing pocket depth (PPD), bleeding on probing (BOP) and clinical attachment level (CAL) (p = 0.038, 0.004, 0.004 and 0.002, respectively) in RA. Anti-P. gingivalis antibody titers were not correlated with disease activity score 28 (DAS28) or anti-CCP titer. However, anti-ENO1 antibody titers were significantly correlated not only with the periodontal indices, such as PPD, BOP, and CAL (p = 0.013, 0.023 and 0.017, respectively), but also RA clinical characteristics, such as DAS28, anti-CCP titer, and ESR (p = 0.009, 0.015 and 0.001, respectively). Anti-P. gingivalis and anti-ENO1 antibody titers were correlated with the severity of PD in RA. Anti-ENO1 antibody titers, but not anti-P. gingivalis antibody titers, were further associated with RA disease activity. The online version of this article (doi:10.1186/s12891-015-0647-6) contains supplementary material, which is available to authorized users.